Prognostic value of texture analysis of the primary tumour in high-risk neuroblastoma: An
18F-DOPA
PET
neuroblastoma
prognosis
radiomics
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
revised:
22
06
2022
received:
21
04
2022
accepted:
14
07
2022
pubmed:
4
8
2022
medline:
1
10
2022
entrez:
3
8
2022
Statut:
ppublish
Résumé
To evaluate the prognostic value of texture analysis of the primary tumour with We retrospectively analysed 18 patients with HR-NBL, which had been prospectively enrolled in the course of a previous trial investigating the diagnostic role of There was a direct correlation between WBMB and radiomics parameter describing uptake intensity (SUV Textural parameters describing heterogeneity and metabolic intensity of the primary HR-NBL are closely associated with its overall metastatic burden. In turn, the whole-body tumour load appears to be one of the most relevant predictors of progression-free and overall survival.
Substances chimiques
N-Myc Proto-Oncogene Protein
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Fluorine
284SYP0193
fluorodopa F 18
2C598205QX
Dihydroxyphenylalanine
63-84-3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29910Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Morgenstern DA, Pötschger U, Moreno L, et al. Risk stratification of high-risk metastatic neuroblastoma: a report from the HR-NBL-1/SIOPEN study. Pediatr Blood Cancer. 2018;65(11):e27363.
Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2009;27(2):289-297.
Tolbert VP, Matthay KK. Neuroblastoma: clinical and biological approach to risk stratification and treatment. Cell Tissue Res. 2018;372(2):195-209.
Vasudevan SA, Nuchtern JG. Gene profiling of high risk neuroblastoma. World J Surg. 2005;29(3):317-324.
Pinto NR, Applebaum MA, Volchenboum SL, et al. Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 2015;33(27):3008-3017.
Sokol E, Desai AV, Applebaum MA, et al. Age, diagnostic category, tumor grade, and mitosis-karyorrhexis index are independently prognostic in neuroblastoma: an INRG project. J Clin Oncol. 2020;38(17):1906-1918.
Moreno L, Guo D, Irwin MS, et al. A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: an International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2021;68(3):e28794.
Campbell K, Shyr D, Bagatell R, et al. Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: a report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2019;66(8):e27819.
Voeller J, Sondel PM. Advances in anti-GD2 immunotherapy for treatment of high-risk neuroblastoma. J Pediatr Hematol Oncol. 2019;41(3):163-169.
Ryan AL, Akinkuotu A, Pierro A, Morgenstern DA, Irwin MS. The role of surgery in high-risk neuroblastoma. J Pediatr Hematol Oncol. 2020;42(1):1-7. https://doi.org/10.1097/MPH.0000000000001607
Park JR, Kreissman SG, London WB, et al. Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial. JAMA. 2019;322(8):746-755.
Arumugam S, Manning-Cork NJ, Gains JE, Boterberg T, Gaze MN. The evidence for external beam radiotherapy in high-risk neuroblastoma of childhood: a systematic review. Clin Oncol (R Coll Radiol). 2019;31(3):182-190.
Feng J, Cheng FW, Leung AW, et al. Upfront consolidation treatment with (131)I-mIbG followed by myeloablative chemotherapy and hematopoietic stem cell transplantation in high-risk neuroblastoma. Pediatr Investig. 2020;4(3):168-177.
Sarioglu FC, Salman M, Guleryuz H, et al. Radiological staging in neuroblastoma: computed tomography or magnetic resonance imaging? Pol J Radiol. 2019;84:e46-e53.
Gassenmaier S, Tsiflikas I, Maennlin S, Urla C, Warmann SW, Schaefer JF. Retrospective accuracy analysis of MRI based lesion size measurement in neuroblastic tumors: which sequence should we choose? BMC Med Imaging. 2020;20(1):105.
Brisse HJ, McCarville MB, Granata C, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group project. Radiology. 2011;261(1):243-257.
Schmidt M, Simon T, Hero B, Schicha H, Berthold F. The prognostic impact of functional imaging with 123I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97. Eur J Cancer. 2008;44(11):1552-1558.
Matthay KK, Shulkin B, Ladenstein R, et al. Criteria for evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer. 2010;102(9):1319-1326.
Rogasch JMM, Hundsdoerfer P, Furth C, et al. Individualized risk assessment in neuroblastoma: does the tumoral metabolic activity on 123I-MIBG SPECT predict the outcome? Eur J Nucl Med Mol Imaging. 2017;44(13):2203-2212.
Lu MY, Liu YL, Chang HH, et al. Characterization of neuroblastic tumors using 18F-FDOPA PET. J Nucl Med. 2013;54(1):42-49.
Piccardo A, Lopci E, Conte M, et al. Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. Eur J Nucl Med Mol Imaging. 2012;39(1):57-71.
Piccardo A, Morana G, Puntoni M, et al. Diagnosis, treatment response, and prognosis: the role of (18)F-DOPA PET/CT in children affected by neuroblastoma in comparison with 123I-mIBG scan: the first prospective study. J Nucl Med. 2020;61(3):367-374.
Lopci E, Piccardo A, Nanni C, et al. 18F-DOPA PET/CT in neuroblastoma: comparison of conventional imaging with CT/MR. Clin Nucl Med. 2012;37(4):e73-e78.
Szychot E, Morgenstern D, Chopra M, et al. Clinical impact of primary tumour 123I-mIBG response to induction chemotherapy in children with high-risk neuroblastoma. Int J Clin Oncol. 2022;27(1):253-261.
Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14(12):749-762.
Lambin P, Rios-Velazquez E, Leijenaar R, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012;48(4):441-446.
Scapicchio C, Gabelloni M, Barucci A, Cioni D, Saba L, Neri E. A deep look into radiomics. Radiol Med. 2021;126(10):1296-1311.
Bar-Sever Z, Biassoni L, Shulkin B, et al. Guidelines on nuclear medicine imaging in neuroblastoma. Eur J Nucl Med Mol Imaging. 2018;45(11):2009-2024.
Piccardo A, Puntoni M, Lopci E, et al. Prognostic value of ¹⁸F-DOPA PET/CT at the time of recurrence in patients affected by neuroblastoma. Eur J Nucl Med Mol Imaging. 2014;41(6):1046-1056.
Fiz F, Costa G, Gennaro N, et al. Contrast administration impacts CT-based radiomics of colorectal liver metastases and non-tumoral liver parenchyma revealing the “radiological” tumour microenvironment. Diagnostics (Basel). 2021;11(7):1162.
Nioche C, Orlhac F, Boughdad S, et al. LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res. 2018;78(16):4786-4789.
Dercle L, Ammari S, Bateson M, et al. Limits of radiomic-based entropy as a surrogate of tumor heterogeneity: ROI-area, acquisition protocol and tissue site exert substantial influence. Sci Rep. 2017;7(1):7952.
van Griethuysen JJM, Fedorov A, Parmar C, et al. Computational radiomics system to decode the radiographic phenotype. Cancer Res. 2017;77(21):e104-e107.
Thibault G, Angulo J, Meyer F. Advanced statistical matrices for texture characterization: application to cell classification. IEEE Trans Biomed Eng. 2014;61(3):630-637.
Boeva V, Louis-Brennetot C, Peltier A, et al. Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries. Nat Genet. 2017;49(9):1408-1413.
Thole TM, Toedling J, Sprussel A, et al. Reflection of neuroblastoma intratumor heterogeneity in the new OHC-NB1 disease model. Int J Cancer. 2020;146(4):1031-1041.
Kong J, Sertel O, Shimada H, Boyer KL, Saltz JH, Gurcan MN. Computer-aided evaluation of neuroblastoma on whole-slide histology images: classifying grade of neuroblastic differentiation. Pattern Recognit. 2009;42(6):1080-1092.
Sertel O, Kong J, Shimada H, Catalyurek UV, Saltz JH, Gurcan MN. Computer-aided prognosis of neuroblastoma on whole-slide images: classification of stromal development. Pattern Recognit. 2009;42(6):1093-1103.
Ahmed AA, Zhang L, Reddivalla N, Hetherington M. Neuroblastoma in children: update on clinicopathologic and genetic prognostic factors. Pediatr Hematol Oncol. 2017;34(3):165-185.
Meany HJ, London WB, Ambros PF, et al. Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2014;61(11):1932-1939.
Maris JM. The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr Opin Pediatr. 2005;17(1):7-13.
Cangelosi D, Morini M, Zanardi N, et al. Hypoxia predicts poor prognosis in neuroblastoma patients and associates with biological mechanisms involved in telomerase activation and tumor microenvironment reprogramming. Cancers (Basel). 2020;12(9):2343.
Swadi RR, Sampat K, Herrmann A, Losty PD, See V, Moss DJ. CDK inhibitors reduce cell proliferation and reverse hypoxia-induced metastasis of neuroblastoma tumours in a chick embryo model. Sci Rep. 2019;9(1):9136.
Qian L, Yang S, Zhang S, et al. Prediction of MYCN amplification, 1p and 11q aberrations in pediatric neuroblastoma via pre-therapy 18F-FDG PET/CT radiomics. Front Med (Lausanne). 2022;9:840777.
Påhlman S, Mohlin S. Hypoxia and hypoxia-inducible factors in neuroblastoma. Cell Tissue Res. 2018;372(2):269-275.
Huertas-Castaño C, Gómez-Muñoz MA, Pardal R, Vega FM. Hypoxia in the initiation and progression of neuroblastoma tumours. Int J Mol Sci. 2019;21(1):39.